Abstract:
The repurposing of known drugs is vital for the development of safe and cost-effective treatments for a wide range of conditions. We saw this during the COVID-19 pandemic, where known drugs like dexamethasone were repurposed for the treating of patients who were critically ill with COVID. Similarly, although Aspirin was developed over 100 years ago for treating pain and fever, it is currently undergoing Phase III Clinical Trials for treating colon and other cancers.

In this webinar, Hsu Min will provide an overview of the case law that has been developed so far and highlight the do’s and don’ts for companies trying to navigate this space, and what steps can be taken to ensure that you can exploit a drug for its “off-patent” use while minimising risks of infringement of any “live” patents for new indications of the drug.

Date/Time: 07 Sep, 16:00 -17:00 (HKT)

Venue: Zoom (Register Now)

Speaker:
Hsu Min Chung (Partner of HGF Limited)

Speaker's Bio:
Hsu Min specialises in patents in the fields of chemistry, material science and pharmaceuticals. Her experience includes drafting and prosecuting patent applications in a wide range of technologies, including those relating to pharmaceuticals, catalytic processes, household products, electrochemistry, medical devices and polymers.

Hsu Min has vast experience in European Oppositions and Appeals and regularly represents clients at Oral proceedings at the European Patent Office. She manages substantial patent portfolios and provides clients with opinions on their freedom-to-operate in light of third party rights. She works for a variety of clients including universities, start-ups and multi-national corporations.

Hsu Min has a First Class Masters’ Degree in Chemistry from Oxford University. She started in the patent profession in private practice in 1996, before joining the in-house patent department of a FTSE 100 multinational Oil & Gas company. She joined HGF as a Partner in 2011.